IDS - 11/13/2006

I hereby certify that this correspondence is being 13 2006 deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on November 6 2006

Glenn P. Ladwig, Patent Attorney

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Examining Group 1632 Patent Application Docket No. USF-182XC1 Serial No. 10/655,873

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Louis D. Lieto. Ph.D.

/Marcia Noble/

Art Unit

1632

Applicants

Shyam S. Mohapatra, Mukesh Kumar

Serial No.

10/655,873

Filed

September 5, 2003

For

Genetic Adjuvants for Immunotherapy

MS AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

11/13/2006 CNEGA1 00000004 190065 10655873

03 FC:1806

180.00 DA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

Docket No.: USF-182XC1

Serial No.: 10/655,873

The applicants respectfully assert that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Glenn P. Ladwig Patent Attorney

Registration No. 46,853

Phone No.:

352-375-8100

Fax No.:

352-372-5800

Address:

P.O. Box 142950

Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (1 page); copies of references cited therein

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB Under the Paperwork

control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Con	npiete ir Know <u>n</u>	
Application Number	10/655,873	
Filing Date	September 5, 2003	
First Named Inventor	Shyam S. Mohapatra	
Group Art Unit	1632	
Examiner Name	Louis D. Lieto, Ph.D. Marcia	Mdble/
Attorney Docket Number	USF-182XC1	ノ

Sheet NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the Cite Examiner item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Initials' No. number(s), publisher, city and/or country where published. GILL, D.R. et al. "The development of gene therapy for diseases of the lung" Cell. Mol. Life Sci., 2004, 61:355-MN 368. R1 PERRICONE, M.A. et al. "Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic MN fibrosis. II. Transfection efficiency in airway epithelium" Human Gene Therapy, 2001, 12:1383-1394. R2 "Gene" from The American Heritage Dictionary of the English Language, 4th Ed. (online), 2000 (retrieved on 2006-MN 06-15). Retrieved from the Internet: <URL: http://dictionary.reference.com/browse/gene>. R3 "Timolol Maleate" from RxList The Internet Drug Index (online), 2006 (retrieved on 2006-06-15). Retrieved from the Internet: <URL: http://www.rxlist.com/cgi/generic3/timololgfs_wcp.htm>. MN R4 "Respiratory tract" from Wikipedia (online), 2006 (retrieved on 2006-06-15). Retrieved from the Internet: <URL: MN http://en.wikipedia.org/wiki/Respiratory_tract>. R5 R R R R

Examiner	Marcia S.	Digitally signed by Marcia S. Noble DN: cn=Marcia S. Noble, c=US, o=USPTO, ou=AU 1832, email=Mercia.	/Marcia	Noble/	Date	01/22/2007
Signature	Noble	Noble@uspto.gov Date: 2007.01.22.21:01:58 -05007			Considered	
*EXAMINER: Initial i	f reference considered,	whether or not citation	is in conformance	with MPEP 60	09. Draw line the	rough citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including application. Confidentiality is governed application form to the USPTO. The will have decoding upon the individual application form to the USPTO. The will have decoding upon the individual applicant. gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.